Want to see SMMT full AI Analyst Report?
SMMT Stock Chart & Stats
$13.66
-$0.55(-4.06%)
At close: 4:00 PM EDT
$13.66
-$0.55(-4.06%)
Day’s Range― - ―
52-Week Range$12.25 - $30.98
Previous Close$13.23
Volume4.23M
Average Volume (3M)4.74M
Market Cap
$10.39B
Enterprise Value$10.67K
Total Cash (Recent Filing)$690.68M
Total Debt (Recent Filing)$20.38M
Price to Earnings (P/E)―
Beta3.15
Next Earnings
Nov 11, 2026EPS Estimate
-0.28Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.12
Shares Outstanding797,749,600
10 Day Avg. Volume3,764,348
30 Day Avg. Volume4,737,289
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)26.74
Price to Sales (P/S)0.00
P/FCF Ratio-54.45
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$27.68Price Target Upside102.64% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering12
EPS Forecast (FY)-1.09
Revenue Forecast (FY)$3.21M
Bulls Say, Bears Say
Bulls Say
Strong Cash BalanceA cash and investments balance of $690.7M materially improves Summit's near-to-midterm financial flexibility, funding ongoing global Phase III programs and regulatory activities without immediate commercial revenue. This supports runway, trial execution and potential launch prep over coming months.
Regulatory Progress And Phase III SurvivalBLA acceptance and a set PDUFA date are durable regulatory milestones that crystallize approval timing risk and opportunity. Combined with Phase III overall survival (HR 0.76) and no new safety signals, these data materially strengthen the company's approval and commercial prospects in EGFR-mutated NSCLC.
Broad Clinical Footprint And CollaborationsLarge patient exposure, completed enrollments across HARMONi programs and strategic collaborations (Arcus, Revolution, Akeso partnership) validate ivonescimab's development pathway, expand combinatorial opportunities, and support global development and potential market access beyond a single geography.
Bears Say
Pre-revenue And Large LossesAs a pre-revenue biotech, Summit lacks recurring commercial sales and posts substantial operating losses; until a product achieves approval and commercialization, negative earnings constrain free cash flow generation and make long-term sustainability dependent on successful approval and market uptake.
Consistent Negative Cash FlowPersistent negative operating and free cash flow, with worsening TTM burn, creates a structural funding requirement. Even with strong cash on hand, the burn trajectory can shorten runway, forcing resource reallocation or external financing that may affect development timelines and strategic flexibility.
Reliance On Collaborations And Equity FinancingRevenue mix relies on milestone-based collaborations and licensing; the new $380M ATM underscores dependence on equity markets to fund operations. This model creates recurring financing risk and potential dilution, which can constrain long-term capital structure and investor-aligned incentives absent product revenue.
Summit Therapeutics News
SMMT FAQ
What was Summit Therapeutics’s price range in the past 12 months?
Summit Therapeutics lowest stock price was $12.25 and its highest was $30.98 in the past 12 months.
What is Summit Therapeutics’s market cap?
Summit Therapeutics’s market cap is $10.39B.
When is Summit Therapeutics’s upcoming earnings report date?
Summit Therapeutics’s upcoming earnings report date is Nov 11, 2026 which is in 100 days.
How were Summit Therapeutics’s earnings last quarter?
Summit Therapeutics released its earnings results on Jul 23, 2026. The company reported -$0.28 earnings per share for the quarter, missing the consensus estimate of -$0.274 by -$0.006.
Is Summit Therapeutics overvalued?
According to Wall Street analysts Summit Therapeutics’s price is currently Undervalued.
Does Summit Therapeutics pay dividends?
Summit Therapeutics does not currently pay dividends.
What is Summit Therapeutics’s EPS estimate?
Summit Therapeutics’s EPS estimate is -0.28.
How many shares outstanding does Summit Therapeutics have?
Summit Therapeutics has 797,749,600 shares outstanding.
What happened to Summit Therapeutics’s price movement after its last earnings report?
Summit Therapeutics reported an EPS of -$0.28 in its last earnings report, missing expectations of -$0.274. Following the earnings report the stock price went down -8.812%.
Which hedge fund is a major shareholder of Summit Therapeutics?
Currently, no hedge funds are holding shares in SMMT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Summit Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$27.68 (102.64% Upside)
$27.68 (102.64% Upside)
Blogger Sentiment
Bullish
SMMT Sentiment 78%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth $103.6M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 2.6%
Last 30 Days ▼ 2.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-50.45%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
132.13%
Trailing 12-Months
Company Description
Summit Therapeutics
Summit Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing therapeutic solutions, primarily targeting infectious diseases across the United States and Latin America. The company's clinical development pipeline is heavily concentrated on therapies for Clostridioides difficile infection (CDI). Its flagship product candidate, ridinilazole, is an orally administered small molecule antibiotic currently advancing through Phase III clinical trials as a treatment for CDI. Beyond its lead asset, Summit Therapeutics is also progressing SMT-738, designed to combat multidrug-resistant infections, notably carbapenem-resistant Enterobacteriaceae (CRE). Additionally, its DDS-04 series represents a potential therapeutic avenue for various infections caused by the Enterobacteriaceae family of bacteria. Established in 2003, the company maintains its headquarters in Cambridge, Massachusetts.
SMMT Company Deck
SMMT Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a strong set of clinical and operational achievements: multiple positive Phase III readouts, broad global development, robust patient exposure, strategic collaborations, a healthy cash balance ($713.4M), manufacturing transfer to the U.S., and an accepted BLA with a November 14, 2026 PDUFA date. Key risks remain around demonstrating statistically significant overall survival for U.S. approval in the EGFR setting, OS immaturity at the interim PFS readout for HARMONi-3 squamous, increased near-term R&D spending (non-GAAP op expenses +~9.6% Q/Q), and reliance on partner-generated data from China which may require bridging for global regulatory bodies. On balance, the highlights (clinical momentum, approvals in China, partnerships, cash runway, manufacturing readiness) outweigh the challenges, but the path to full U.S. approval and broader commercialization depends on forthcoming OS data and regulatory interactions.View all SMMT earnings summariesSMMT Stock 12 Month Forecast
Average Price Target
$27.68
▲(102.64% Upside)